Syn-The-All (STA) Pharmaceuticals Co., Ltd., a manufacturing subsidiary of WuXi PharmaTech has begun construction of a new and fully integrated R&D and cGMP manufacturing site in Changzhou, 110 miles west of Shanghai, China. This construction is aimed at fulfilling the rapidly increasing demands of WuXi’s manufacturing services.
This new facilities will be constructed in phases. The campus will include research manufacturing facilities as well as commercial manufacturing facilities. The facilities constructed in phase 1 would be more than double the company's existing manufacturing capacity. The first phase would be operational by the fourth quarter of 2015.
Once the entire project is complete, the campus would more than triple the present manufacturing capacity of the organisation. The overall employment generated would be around 1,500. It would include chemists, production staff, and support staff, who would seamlessly move new chemical entities from the early stages of process development through to preclinical and clinical deliveries for ultimate commercial production.
